Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines
Rhea-AI Summary
Tivic Health (Nasdaq: TIVC) will host a special webcast and conference call on Monday, January 12, 2026 at 1:30 PM PT / 4:30 PM ET to discuss its December 2025 acquisition of certain CDMO assets, now branded Velocity Bioworks. Management said the in‑house CDMO has already reduced outsourcing delays and costs, accelerated validation of Entolimod™ manufacturing, and may enable an earlier biologics license application submission to the U.S. FDA. Leadership expects Velocity Bioworks to operate as a standalone CDMO and a new revenue engine by providing biologic production services to small and midsize development-stage biotech companies. The call will feature CEO Jennifer Ernst and COO Michael K. Handley and is accessible via webcast and dial-in.
Positive
- Acquisition of CDMO assets completed in December 2025, branded Velocity Bioworks
- In-house manufacturing reportedly lowers costs and removes outsourcing delays
- Management expects earlier FDA biologics license application timing for Entolimod™
- New revenue engine from third-party biologic production for small/mid biotech
Negative
- None.
News Market Reaction
On the day this news was published, TIVC gained 5.97%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.3% during that session. Argus tracked a trough of -13.0% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $134K to the company's valuation, bringing the market cap to $2M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TIVC fell 6.94% while peers were mixed: NAOV -1.95%, MOVE -3.35%, NUWE -2.43%, AMIX -4.92%, and VERO +2.01%, pointing to stock-specific pressure rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | CDMO acquisition | Positive | +11.8% | Acquired cGMP assets and launched Velocity Bioworks with sizable financing. |
| Nov 18 | Regulatory meeting | Positive | +25.1% | Secured BARDA Techwatch meeting to discuss Entolimod data and BLA path. |
| Nov 14 | Q3 2025 earnings | Negative | -8.2% | Reported small revenue, operating loss and cash balance amid transformation. |
| Nov 13 | Clinical study data | Positive | -7.1% | ncVNS optimization trial showed improved HRV and impact of personalized settings. |
| Nov 06 | Earnings call notice | Neutral | -9.7% | Announced timing and access details for upcoming Q3 earnings webcast. |
Recent Tivic headlines often produced sizeable moves, with positive strategic or regulatory updates tending to align with price gains, while scientific data and routine calls sometimes saw negative or contrary reactions.
Over the last few months, Tivic has shifted toward biologics and manufacturing scale-up. On Nov 6, it scheduled Q3 results via webcast, followed by Q3 earnings on Nov 14 showing modest $146,000 revenue and a $2.6M net loss, which coincided with share weakness. Later November news on a BARDA Techwatch meeting for Entolimod and a clinical optimization trial in ncVNS underscored R&D progress but drew mixed price reactions. The Dec 11 acquisition of cGMP assets and launch of Velocity Bioworks, backed by a structured financing package, saw a positive 11.76% move, framing today’s webcast as a follow-on to that strategic shift.
Regulatory & Risk Context
An effective S-3 resale registration dated Oct 17, 2025 covers up to 1,580,437 shares of common stock for selling stockholders. The company is not selling shares in this filing and would only receive cash upon any warrant exercises. The shelf has seen at least 2 related 424B3 prospectus supplements, indicating active use for registered resales.
Market Pulse Summary
The stock moved +6.0% in the session following this news. A strong positive reaction aligns with how Tivic previously responded to its Dec 11 CDMO acquisition, which coincided with an 11.76% move. The webcast elaborates on cost reductions, accelerated Entolimod timelines, and new CDMO revenue, building on that story. Investors would still have to weigh ongoing losses, existing resale registrations covering 1,580,437 shares, and execution risk at Velocity Bioworks when assessing durability.
Key Terms
contract development and manufacturing organization technical
cdmo technical
biologics license application regulatory
AI-generated analysis. Not financial advice.
Conference Call to be Hosted on Monday, January 12 at 1:30 PM PT/4:30 PM ET
FREMONT, CA / ACCESS Newswire / January 8, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that Management will host a special conference call to further discuss the company's recent acquisition of certain contract development and manufacturing organization (CDMO) assets as announced on December 11, 2025. The call will cover how the acquisition has accelerated key strategic priorities and development and commercialization timelines, as well as discuss other near-term potential benefits.
WHO: | Jennifer Ernst, Chief Executive Officer of Tivic |
Michael K. Handley, Chief Operating Officer of Tivic and President of Tivic Biopharma | |
WHEN: | Monday, January 12, 2026 -1:30 PM Pacific Time / 4:30 PM Eastern Time |
Questions can be submitted in advance to ir@tivichealth.com. | |
WEBCAST URL: | |
DIAL-IN NUMBERS: | Toll Free: 888-506-0062 |
International: 973-528-0011 | |
Participant Access Code: 525246 |
"Tivic's acquisition of CMDO assets, now branded Velocity Bioworks, in December 2025 capped a year of dramatic transformation for Tivic," stated Jennifer Ernst, CEO of Tivic. "As an in-house manufacturing resource, it already has had the intended impact of lowering costs, removing outsourcing delays, and accelerating the validation of the manufacturing process of Entolimod™. In fact, we believe it will enable us to submit a biologics license application to the U.S. Food and Drug Administration ahead of schedule, compared to other outsourcing options. As a stand-alone CDMO, Velocity Bioworks has become a new revenue engine for Tivic and is built to deliver fast, high-quality biologic production for third-party customers, filling an area of unmet need for small and medium sized development-stage biotechnology companies."
About Tivic Health Systems, Inc.
Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's pipeline includes lead drug candidate, Entolimod™ for acute radiation syndrome, neutropenia, and to treat lymphocyte exhaustion, as well as Entolasta™, which is an immunologically optimized variant of Entolimod™ for chronic applications. To learn more about Tivic, visit: https://ir.tivichealth.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the U.S. Food and Drug Administration (FDA) and other regulatory authorities; the ability of the company to achieve the expected benefits from the acquisition of CDMO assets within expected time frames or at all; changes to the company's relationship with its partners; timing of submission of a biologics license application to the FDA; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod™ and Entolasta™; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in the future; the potential opportunities that may be available to the company and its product candidates in the future; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading "Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Media Contact:
DJ@FastrackPR.com
SOURCE: Tivic Health Systems
View the original press release on ACCESS Newswire
FAQ
When is Tivic (TIVC) hosting the webcast to discuss the CDMO acquisition?
Who will present on the Tivic (TIVC) special call about Velocity Bioworks?
How does Tivic say the Velocity Bioworks acquisition affects Entolimod™ development timelines?
What is Velocity Bioworks' planned business role after Tivic's acquisition?
How can investors access Tivic's January 12, 2026 webcast for TIVC?
